PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice
Bradley A. Zinker(Abbott (United States)), Michael R. Jirousek(Abbott Fund), Seth D. Crosby(Abbott (United States)), Sanjay Bhanot(Ionis Pharmaceuticals (United States)), Robert A. McKay(Ionis Pharmaceuticals (United States)), Jill E. Clampit(Abbott (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Cristina M. Rondinone(Abbott Fund), Regina M. Reilly(Abbott (United States)), Rebecca J. Gum(AbbVie (United States)), Peer B. Jacobson(AbbVie (United States)), Terry J. Opgenorth(Abbott (United States)), Leigh Frost(Abbott (United States)), Sandra Koterski(Abbott (United States)), James M. Trevillyan(Abbott (United States)), Jeffrey F. Waring(AbbVie (United States)), Paul E. Kroeger(Abbott (United States)), Susan F. Murray(Abbott (United States)), Roger G. Ulrich(Vifor Pharma (United States)), Madeline Butler(Abbott (United States)), Denise Wilcox(Abbott (United States)), Nancy Xie(Abbott (United States))
Cited by 415
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k